Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,582 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 20 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus, Pregnancy in Diabetes
Interventions: Hybrid closed-loop therapy, Sensor-augmented pump therapy; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Columbus, Ohio

Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab; Drug
Lead sponsor: Aulos Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more

Conditions: Type1diabetes
Interventions: Mixed Meal Tolerance Test; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes Mellitis
Interventions: Hybrid Closed Loop (HCL) x 2 weeks, AIDANET x 2 weeks, AIDANET AI x 4 weeks; Device
Lead sponsor: Sue Brown; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 70
States / cities: Little Rock, Arkansas • Concord, California • Encino, California + 60 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Positive Affect, Education; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 13 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: T1DM - Type 1 Diabetes Mellitus
Interventions: 13 CGM (continuous glucose monitor); Device
Lead sponsor: Sinocare; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Concord, California • Escondido, California • La Jolla, California + 30 more

Conditions: Type1diabetes
Interventions: Quick Bolus, Standard Bolus; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: C-Carbs Program; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions: Islet Cell Transplant; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Enlite Sensor; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Chula Vista, California • Escondido, California • La Jolla, California + 4 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Burlingame, California • Tallahassee, Florida

Conditions: Type 1 Diabetes
Interventions: Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions: VX-880, VX-017; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 12
States / cities: Duarte, California • San Francisco, California • Miami, Florida + 8 more

Conditions: Type 1 Diabetes
Interventions: Terbutaline; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 12 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed Loop Control (CLC), Open Loop; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Xeris glucagon, Lilly glucagon; Drug
Lead sponsor: Steven J. Russell, MD, PhD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Dehydroepiandrosterone, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: Human Pancreatic Islets; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2033
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes,, Bone
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 50 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Type 1 Diabetes
Interventions: Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician; Device · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 7 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more

Conditions: Type 1 Diabetes
Interventions: Family-based cognitive-behavioral treatment; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress

Pregnancy Intervention With a Closed-Loop System (PICLS) Study

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Development of Predictive Biomarkers

Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes

C-Carbs: A CGM-guided Approach to Teaching Carb Awareness

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use

Green Digital Diabetes Waste Project

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes

Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

Islet Allotransplantation in Type 1 Diabetes

Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

Supporting Treatment Adherence Needs in Diabetes